Alogliptin’s European drug application triggers $10M milestone for FURX
Type 2 diabetes drug alogliptin may have fallen short of regulatory approval in the United States, but its latest progress overseas is paying off for Furiex Pharmaceuticals (NASDAQ:FURX) in the form of a $10 million milestone payment. The marketing authorization application filed by drug partner Takeda Pharmaceutical (TYO:4502) was accepted and triggered the payment to […]